Reference
- Monreal, M. and Davant, E. (2001) "Thrombotic complications of central venous catheters in cancer patients", Acta Haematol., 106, 69–72.
- Bona, R.D. (1999) "Thrombotic complications of central venous catheters in cancer patients", Semin. Thromb. Hemost., 25, 147–155.
- Drakos, P.E., Nagler, A., Or, R., Gillis, S., Slavin, S. and Eldor, A. (1992) "Low molecular weight heparin for Hickman catheter-induced thrombosis in thrombocytopenic patients undergoing bone marrow transplantation", Cancer, 70, 1895— 1898.
- Cortelezzia, A., Fracchiolla, N.S., Maisonneuve, P., Moia, M., Luchesini, C., Ranzi, M.L., et al. (2003) "Central venous catheter-related complications in patients with hematological malignancies: a retrospective analysis of risk factors and prophylactic measures", Leuk. Lymphoma, 44, 1495–1501.
- Monreal, M., Lafoz, E., Ruiz, J., Valls, R. and Alastrue, A. (1991) "Upper-extremity deep venous thrombosis and pulmonary embo-lism. A prospective study", Chest, 99, 280–283.
- Monreal, M., Raventos, A., Lerma, R., Ruiz, J., Lafoz, E., Alastrue, A., et al. (1994) "Pulmonary embolism in patients with upper extremity DVT associated to venous central lines-prospective study", Thromb. Haemost., 72, 548–550.
- Frank, D.A., Meuse, J., Hirsch, D., Ibrahim, J.G. and van den Abbeele, A.D. (2000) "The treatment and outcome of cancer patients with thromboses on central venous catheters", J. Thromb. Thrombolysis, 10, 271–275.
- Weitz, J.I. (1997) "Low-molecular-weight heparins", N. Engl. J. Med., 337, 688 — 698.
- Warkentin, T.E., Levine, M.N., Hirsh, J., Horsewood, P., Roberts, R.S., Gent, M., etal. (1995) "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractio-nated heparin", N. Engl. J. Med., 332, 1330–1335.
- De Candia, E., De Cristofaro, R. and Landolfi, R. (1999) "Thrombin-induced platelet activation is inhibited by high- and low-molecular-weight heparin", Circulation, 99, 3308 — 3314.
- Home, M.K. III and Chao, E.S. (1990) "The effect of molecular weight on heparin binding to platelets", Br. J. Haematol., 74, 306 — 312.
- Carter, C.J., Kelton, J.G., Hirsh, J., Cerskus, A., Santos, A.V. and Gent, M. (1982) "The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits", Blood, 59, 1239–1245.
- Levine, M.N., Raskob, G., Landefeld, S. and Kearon, C. (2001) "Hemorrhagic complications of anticoagulant treatment", Chest, 119, 108S–121S.
- Or, R., Nagler, A., Shpilberg, 0., Elad, S., Naparstek, E., Kapelushnik, J., et al. (1996) "Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients", Transplantation, 61, 1067 — 1071.
- Simon, M., Hahn, T., Ford, L.A., Anderson, B., Swinnich, D., Baer, M.R., et al. (2001) "Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin", Bone Marrow Transplant., 27, 627–633.
- Forrest, D.L., Thompson, K., Dorcas, V.G., Couban, S.H. and Pierce, R. (2003) "Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study", Bone Marrow Transplant., 31, 1143–1149.
- Holst, J., Lindblad, B., Bergqvist, D., Garre, K., Nielsen, H., Hedner, U., et al. (1994) "Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logi-parin). An experimental investigation in healthy volunteers", Blood Coagul. Fibrinolysis, 5, 795–803.